ANDREW GARAZHA, HEAD OF INFORMATION TECHNOLOGY
Andrew Garazha is a Head of IT Department. He earned his bachelor degree in Applied Mathematics and Physics and master degree in Biotechnology at Moscow Institute of Physics and Technology. Andrew also worked as a researcher at the California Institute of Technology, the Institute of Bioorganic Chemistry of the Russian Academy of Sciences and the Federal Clinical Center of Oncology, Immunology and Hematology. Now he is working on business development of the First Oncology Research and Advisory Center and the Aging Analytics Agency.
We are a group of doctors and researches dedicated to the development of a unique molecular approach to serious medical conditions, particularly cancer.
PHD, DSC CEO
Dr. Anton Buzdin is the founder of OncoFinder Project. He has graduated from Moscow State University, Faculty of Biology, Department of Molecular Biology in 1999. In January 2003, Dr. Buzdin defended his PhD thesis in Molecular Biology entitled “Experimental recovery and characterization of human-specific transposable elements”. Since 2005, Dr. Buzdin as been the head of a research laboratory at Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia. In 2008, Dr. Buzdin defended Doctor of Sciences” (D.Sc.) thesis in Molecular Biology under the guidance of Prof. Eugene D. Sverdlov, also at Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry. His thesis focused on bioinformatics, systems biology and new methods of processing large-scale biochemical and molecular biology datasets.
At present, Dr. Buzdin is the head of the team and he also supervises the Laboratory for Systems Biology at Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry and the Laboratory of Bioinformatics and Medical Information Technology at Dima Rogachev Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology (FRCCPHOI), both in Moscow.
Dr. Buzdin has authored > 60 scientific papers in the international peer-reviewed journals in the field of cancer medicine and biology (www.ncbi.nlm.nih.gov), 12 monographs and book chapters, and holds 15 patents. Dr. Buzdin has been awarded with the medals of the European Academy of Sciences (Academia Europaea) and of the Russian Academy of Sciences. Dr. Buzdin has also been awarded with the prestigious Korogodin and Timofeev-Ressovsky medals and prizes.
ALEX ZHAVORONKOV, PHD
Dr. Zhavoronkov is a co-founder of OncoFinder Project. He is a scientist working on biotechnology and regenerative medicine and the director of the Biogerontology Research Foundation, a UK-based think tank for research on aging. Alexander is also the head of the Laboratory of Regenerative Medicine at the Federal Research and Clinical Center for Pediatric Hematology, Oncology and Immunology (FRCCPHOI) in Moscow. His research interests include personalized medicine in oncology, the Hutchinson-Gilford Syndrome, aging-related molecular changes and new methods of cellular reprogramming, and molecular mechanisms of skin and cartilage regeneration.
MD, PROFESSOR, SCIENTIFIC DIRECTOR PONKC
Dr. Zhukov is a scientific director of the First Oncology Research and Advisory Center. He also worked as a Senior Researcher at N.N. Blokhin Cancer Research Center · bone marrow transplantation. At the moment he is the Head of Department at Federal Research and Clinical Centre of Pediatric Hematology, Oncology and Immunology. Nikolay has authored more than 15 published works.
NIKOLAY BORISOV, PHD, DSC
Dr. Nikolay M. Borisov is the Chief R&D Officer and the head of the Laboratory for Cancer Bioinformatics and Systems Biology of Mitogenesis at Burnasyan Federal Medical Biophysical Center, Moscow, Russia. He is also a visiting professor at Moscow Institute of Physics and Technology. Nikolay earned his D.Sc. degree in Engineering in 2008 and Ph.D. degree in Physics and Mathematics in 1999. His scientific interests lie within the domain of mathematical biology and bioinformatics, including, but not limited to, systems biology of cancer and mitogenic signaling pathways, protein-protein interactomics, computational chemical and physical kinetics, Monte Carlo methods, evolutionary algorithms, as well as radiation physics, biology and medicine. He has authored more than 100 published works.
PHD, DSC CEO
Alex Zhavoronkov, PHD
MD, Professor, Scientific Director PONKC
Head of Information Technology
CHARLES CANTOR, PHD (BU, SEQUENOM, AGENA)
Charles Cantor is the former director of the Human Genome Project and is now the director of the Center for Advanced Biotechnology at Boston University. His research interests are human genome analysis, molecular genetics and genetic engineering. Dr. Cantor, in conjunction with David Schwartz, developed pulse field gel electrophoresis for very large molecules. Among his current projects are the development of new methods for faster DNA sequencing, the development of a bacteria strain that will aid in environmental detoxification, and locating the genes for smell and taste. Cantor’s laboratory at Boston University has developed methods for separating large DNA molecules, for studying structural relationships in complex proteins and nucleic acids, and for sensitive detection of proteins and nucleic acids in a variety of settings.
Cantor serves as a consultant to more than 16 biotech firms, has published more than 400 peer reviewed articles, been granted 54 US patents, and co-authored a three-volume textbook on Biophysical Chemistry. He is also a co-founder and Director of Retrotope, a US-based company using heavier isotopes of carbon (C13) and hydrogen (deuterium) to stabilize essential compounds like amino acids, nucleic acids and lipids to target age-related diseases.
Michael Levitt received the 2013 Nobel Prize in Chemistry “for the development of multiscale models for complex chemical systems”, together with Martin Karplus and Arieh Warshel, representing their advancement of chemistry through computer simulation. Levitt was one of the first researchers to conduct molecular dynamics simulations of DNA and proteins and developed the first software for this purpose. He is currently well known for developing approaches to predict macromolecular structures. Dr.
Levitt has served as a professor of structural biology at Stanford University since 1987 and is known for his work in computational biology. His background in computational modeling to understand protein folding processes and molecular interactions is directly applicable to aspects of aging research that Insilico Medicine addresses.
Dr. Levitt is Insilico Medicine’s latest Scientific Advisory Board addition in the pursuit of working interventions towards aging and aging-related disease. Levitt has served on the Scientific Advisory Boards of the following companies: Oplon Ltd, Cocrystal Discovery, StemRad, Ltd, and Cengent Therapeutics, Inc.
PHD (NYU/COLD SPRING HARBOR)
Bud Mishra is a professor of computer science and mathematics at NYU’s Courant Institute of Mathematical Sciences, professor of human genetics Mt Sinai School of Medicine, and a professor of cell biology at NYU School of Medicine. Bud has a degree in Physics from Utkal University, in Electronics and Communication Engineering from Indian Institute of Technology (IIT), Kharagpur, and MS and PhD degrees in Computer Science from Carnegie-Mellon University. Bud is also a visiting scholar at CSHL’s Institute of Quantitative Biology, and an adjunct professor at Tata Institute of Fundamental Research (TIFR) in Mumbai, India. From 2001-04, he was a professor at the Watson School of Biological Sciences, Cold Spring Harbor Lab (CSHL). He has industrial experience in Computer Science (Tartan Laboratories, and ATTAP), Finance (Tudor Investment and PRF, LLC), Robotics and Biotechnology (Abraxis, OpGen, and Bioarrays/Immucor). He is editor of Molecular Cancer Therapeutics, AMRX (Applied Mathematics Research Exchange) and Transactions on Systems Biology, and author of a textbook on algorithmic algebra and more than two hundred archived publications. Bud’s current research is aimed at developing a genomics technology that will enable one to accurately analyze haplotypic data for large-scale human population studies. He has been working also on the evolution of multicellularity and its role in cancer.
MD/PHD (JOHNS HOPKINS MEDICINE)
Donald Small is the director of pediatric oncology at the Johns Hopkins Kimmel Cancer Center. Dr. Small received his undergraduate, and then M.D. and Ph.D. degrees from the Johns Hopkins University in 1979 and 1985. His Ph.D. research was conducted with Bert Vogelstein in the Oncology Department and his postdoctoral research with Tom Kelly in the Molecular Biology and Genetics Department. He trained in pediatrics and pediatric hematology/oncology at Johns Hopkins and joined the faculty in 1990 where he moved up the ranks and is the Kyle Haydock Professor of Oncology with joint appointments in Pediatrics and Cellular and Molecular Medicine and Human Genetics. He has been the Director of Pediatric Oncology since 2006. His laboratory was the first to clone the human FLT3 gene that is the most frequently mutated gene in acute myeloid leukemia (AML) and results in very poor chances of cure for these patients. They investigated its role in leukemia and were the first to discover drugs able to inhibit the tyrosine kinase activity of FLT3. His laboratory showed that this class of drugs would preferentially kill leukemic cell lines and primary AML samples expressing mutant FLT3. Thus, this is one of the first examples of molecularly targeted therapy for cancer. They developed a high-throughput cell-based in vitro assay that enabled them to screen a large library of kinase inhibitors and find several with great potency and selectivity against FLT3. His group led the first clinical trials investigating the use of a FLT3 inhibitor in adult relapsed and refractory FLT3 mutant AML, and determined how to best combine these drugs with chemotherapy. They also helped design the first pediatric trials of FLT3 inhibitors in pediatric AML and infant ALL. His lab continues to study the process of leukemic transformation and the role of FLT3 in leukemia stem cells through the generation of mouse models and by studying signaling changes in these cells.
KRISTEN FORTNEY, PHD (STANFORD)
Kristen Fortney is a postdoctoral fellow of the Aging Research, Ellison Medical Foundation / American Federation for Aging Research at Stanford University. She received her PhD in Bioinformatics from the University of Toronto in 2012. Her current research interests are bioinformatics applied to human aging, especially as it applies to the genetics of human longevity. She is a member of the Stuart Kim Lab of the Stanford Department of Developmental Biology, whose long term goal is to “understand the process of growing old, and then try to slow down or reverse the aging process” by understanding the underlying clock for aging that dictates the rate at which normal aging occurs.
PHD (BU, SEQUENOM, Agena)
PHD (NYU/COLD SPRING HARBOR)
MD/PHD (JOHNS HOPKINS MEDICINE)